BUY Aurobindo Pharma — Kshitija Salvi, Globe Capital Market
byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))27 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Aurobindo Pharma rises 3% after Q1 beat; HDFC Securities retains 'Add', Axis Securities cuts to 'Hold'
NewsGoogle News·7 Aug · today
Hold Aurobindo Pharma; target of Rs 1600: Prabhudas Lilladher
NewsGoogle News·7 Aug · today
3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·7 Aug · today
Aurobindo Pharma Shares Tumble 2% Despite Q1 Profit Jump, Double Digit Revenue Guidance For FY27
NewsNdtv-Profit·6 Aug · yesterday
Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven
NewsNdtv-Profit·6 Aug · yesterday
Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.
NSE · Press Release·5 Aug · yesterday
Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·5 Aug · yesterday
Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries
NewsCnbc-Tv18·24 Jul · 2w ago
Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million
NewsCnbc-Tv18·23 Jul · 2w ago
1 advisor has an active short-term SELL call on this stock, issued in the last 14 days
Advisor consensus · adjacent horizon·6 Aug · yesterday
US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline
NewsHbl·22 Jul · 2w ago
Pharma stocks decline; Aurobindo Pharma down over 4%
NewsHbl·22 Jul · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.